TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34168003

Group type: EXPERIMENTAL
Intervention: Intracerebral administration of ipilimumab (IPI) 10 mg (cohort-1)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Intracerebral administration of ipilimumab (IPI) 5 mg plus nivolumab (NIVO) 10 mg (cohort-2)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Intravenous administration of nivolumab (NIVO) 10 mg, repeated every 2 weeks (max. five administrations)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Historical cohort comparison
Number of subjects: 27
Study: 33099227

Group type: EXPERIMENTAL
Intervention: Growth hormone (1.4 mg every other day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 36484590

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Education intervention
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Provisional PTSD unremitted at 3 months
Number of subjects: 242
Study: 35249543

Group type: EXPERIMENTAL
Intervention: Personalised study invitation letter
Number of subjects: 509

Group type: COMPARATOR
Intervention: Non-personalised study invitation letter
Number of subjects: 509
Study: 34064069

Group type: EXPERIMENTAL
Intervention: WLPB (Weight Loss Program with Bryndza cheese, 30 g daily)
Number of subjects: 22

Group type: COMPARATOR
Intervention: WLP (Weight Loss Program without Bryndza cheese)
Number of subjects: 22
Study: 36322154

Group type: EXPERIMENTAL
Intervention: Clinpro Tooth Crème 0.21% Sodium Fluoride Anti‐Cavity Paste with functional‐Tri Calcium Phosphate (f‐TCP)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: MI Varnish with RECALDENT™ (CPP‐ACP)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Home‐care group (control)
Number of subjects: 105
Study: 33245999

Group type: EXPERIMENTAL
Intervention: Vanillin (pleasant odour)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Thioglycolic acid (TGA, unpleasant odour)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Odourless control condition
Number of subjects: 60
Study: 33551021

Group type: EXPERIMENTAL
Intervention: Qigong Baduanjin intervention (22 weeks)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Qigong Baduanjin intervention
Number of subjects: 186
Study: 34166834

Group type: COMPARATOR
Intervention: GDC-3280 (25–1600 mg single dose)
Number of subjects: 80

Group type: COMPARATOR
Intervention: GDC-3280 (200 mg or 275 mg twice daily for 7 days)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: GDC-3280 (400 mg and 800 mg single dose with food)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: GDC-3280 (400 mg and 800 mg single dose)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: GDC-3280 (repeat doses)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: GDC-3280 (single doses)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: GDC-3280 with rabeprazole
Number of subjects: 80
Study: 33826736

Group type: EXPERIMENTAL
Intervention: Higher degree of self-reported or accelerometer-determined moderate-to-vigorous physical activity
Number of subjects: 329758

Group type: EXPERIMENTAL
Intervention: Longer time spent watching television
Number of subjects: 329758

Group type: EXPERIMENTAL
Intervention: Genetic predisposition to a higher degree of physical activity
Number of subjects: 329758

Group type: EXPERIMENTAL
Intervention: Genetically predicted television watching duration
Number of subjects: 329758
Study: 32936053

Group type: EXPERIMENTAL
Intervention: Listeners higher in dispositional emotional empathy
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Listeners higher in emotional empathy
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Listeners higher in emotional empathy with accurate emotion ratings
Number of subjects: 140
Study: 32475262

Group type: EXPERIMENTAL
Intervention: Self-spent culture medium
Number of subjects: 318

Group type: COMPARATOR
Intervention: New pre-equilibrated culture media
Number of subjects: 318
Study: 35654691

Group type: EXPERIMENTAL
Intervention: encorafenib + cetuximab
Number of subjects: 441

Group type: COMPARATOR
Intervention: ACT/control (cetuximab + irinotecan‐based chemotherapy)
Number of subjects: 441
Study: 33106389

Group type: COMPARATOR
Intervention: Placebo (control group from IMPACT and ASCEND trials)
Number of subjects: 0
Study: 32384122

Group type: EXPERIMENTAL
Intervention: Encala™ treatment
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 66
Study: 36262803

Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormone therapy (NHT) with anastrozole for at least six months (menopausal patients) or anastrozole with subcutaneous goserelin acetate every 12 weeks for at least six months (premenopausal women).
Number of subjects: 130

Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (NCT) with a standard institutional regimen based on anthracyclines and taxanes.
Number of subjects: 130
Study: 34119409

Group type: EXPERIMENTAL
Intervention: Intervention bundle (vitamin C sprays, peppermint water mouthwash, lip moisturiser)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo interventions (saline sprays, 40 °C water mouthwash, wetting lips with water)
Number of subjects: 61
Study: 32591901

Group type: EXPERIMENTAL
Intervention: Intranasal ketamine (1 mg/kg)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Intravenous morphine (0.1 mg/kg)
Number of subjects: 184
Study: 35732396

Group type: EXPERIMENTAL
Intervention: Treatment Group 1 - smart electronic toothbrush, educational booklet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment Group 2 - smart electronic toothbrush, educational booklet, oral hygiene care skill assessment, personalised oral hygiene instruction and treatment plan, in-home and telephone coaching on behaviour change
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group - educational booklet
Number of subjects: 0
Study: 33498165

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 35551845

Group type: EXPERIMENTAL
Intervention: 30 mg of cannabidiol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 35348435

Group type: EXPERIMENTAL
Intervention: Virtual-reality-induced hypnosis
Number of subjects: 153

Group type: COMPARATOR
Intervention: Virtual reality for distraction
Number of subjects: 153

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 153
Study: 33199596

Group type: EXPERIMENTAL
Intervention: Thymectomy
Number of subjects: 0
Study: 35411554

Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy
Number of subjects: 140000

Group type: EXPERIMENTAL
Intervention: FIT
Number of subjects: 140000

Group type: COMPARATOR
Intervention: Demographic and socioeconomic factors
Number of subjects: 140000

Group type: COMPARATOR
Intervention: Colonoscopy after positive FIT
Number of subjects: 140000
Study: 32151503

Group type: EXPERIMENTAL
Intervention: Modified constraint-induced movement therapy (mCIMT), 1 hour therapy sessions for 14 consecutive days, normal arm constrained for 6 hours per day.
Number of subjects: 39

Group type: COMPARATOR
Intervention: Conventional rehabilitation program (control group).
Number of subjects: 39
Study: 37277418

Group type: EXPERIMENTAL
Intervention: 300 mg oral micronized progesterone at bedtime for 3 months
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study: 33549036

Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg with a 240 mg loading dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Galcanezumab (both dosages)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32038017

Group type: EXPERIMENTAL
Intervention: Oral solutions enriched with maltodextrin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard fasting protocols
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbohydrate-enriched drinks
Number of subjects: 0
Study: 35316790

Group type: EXPERIMENTAL
Intervention: Pole Walking (PW) at maximal effort (PWmax)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Walking without poles (W) at maximal effort (Wmax)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Pole Walking (PW) at 80% effort (PW80)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Walking without poles (W) at 80% effort (W80)
Number of subjects: 15
Study: 32993815

Group type: EXPERIMENTAL
Intervention: Prophylactic oral prednisolone 0.5 mg/kg and omeprazole 20 mg single dose 6 h before RAI therapy followed by oral prednisolone 0.5 mg/kg and omeprazole 20 mg daily for 3 days.
Number of subjects: 400

Group type: COMPARATOR
Intervention: Oral placebo and omeprazole 20 mg single dose 6 h before RAI therapy followed by oral placebo and omeprazole 20 mg daily for 3 days.
Number of subjects: 400
Study: 33747373

Group type: EXPERIMENTAL
Intervention: Audiovisual surgical information (video clip)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Regular information only (Control)
Number of subjects: 50
Study: 32631261

Group type: EXPERIMENTAL
Intervention: MCT-OCD (n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Care as usual control group (n = 40)
Number of subjects: 80
Study: 35410282

Group type: EXPERIMENTAL
Intervention: Exercise and advice
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Exercise and advice plus prefabricated orthoses
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Exercise and advice plus custom made orthoses
Number of subjects: 16
Study: 34684562

Group type: EXPERIMENTAL
Intervention: n-3 LCPUFA supplementation (1.6 g of EPA and DHA per day for 12 weeks)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 33438783

Group type: EXPERIMENTAL
Intervention: Empowerment-based cognitive behavioural therapy for insomnia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 32573767

Group type: EXPERIMENTAL
Intervention: Audiovisual animation (3 minutes)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Face-to-face consultation
Number of subjects: 172
Study: 34595827

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg daily
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 33826754

Group type: EXPERIMENTAL
Intervention: Active surveillance
Number of subjects: 965

Group type: COMPARATOR
Intervention: Completion lymph node dissection (CLND)
Number of subjects: 965

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Number of subjects: 965

Group type: EXPERIMENTAL
Intervention: Active surveillance and CLND
Number of subjects: 965
Study: 32886113

Group type: EXPERIMENTAL
Intervention: apo-Lf + FeSO4
Number of subjects: 25

Group type: COMPARATOR
Intervention: FeSO4
Number of subjects: 25

Group type: COMPARATOR
Intervention: holo-Lf
Number of subjects: 25
Study: 35078086

Group type: EXPERIMENTAL
Intervention: Fraction number line game
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Scaffolded fraction number line games
Number of subjects: 188

Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 188
Study: 34939180

Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Innovative quantitative techniques
Number of subjects: 0
Study: 35354006

Group type: EXPERIMENTAL
Intervention: VIP training
Number of subjects: 190
Study: 32417348

Group type: EXPERIMENTAL
Intervention: 75 Gy/35F with IMRT (Arm B)
Number of subjects: 188

Group type: COMPARATOR
Intervention: 70 Gy/35F in 7 weeks with 3D-RT (Arm A)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Dose‐escalated IMRT
Number of subjects: 188
Study: 35397249

Group type: EXPERIMENTAL
Intervention: SWITCH group (monotherapy with either FGA or SGA)
Number of subjects: 136

Group type: COMPARATOR
Intervention: STAY group (combination treatment of FGA and SGA)
Number of subjects: 136
Study: 34929667

Group type: EXPERIMENTAL
Intervention: Community-initiated Kangaroo Mother Care (ciKMC)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control
Number of subjects: 200
Study: 32696522

Group type: EXPERIMENTAL
Intervention: Luspatercept (0.2-1.25 mg/kg, subcutaneously once every 3 weeks)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Luspatercept (1 mg/kg starting dose)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Luspatercept (0.2-1.25 mg/kg)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 285
Study: 33196937

Group type: EXPERIMENTAL
Intervention: Interim methadone treatment
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Increased cocaine use at baseline
Number of subjects: 225
Study: 33166594

Group type: EXPERIMENTAL
Intervention: 25 % silver nitrate (AgNO3) solution followed by 5 % sodium fluoride (NaF) varnish
Number of subjects: 1070

Group type: COMPARATOR
Intervention: 38 % silver diamine fluoride (SDF) solution followed by placebo varnish
Number of subjects: 1070
Study: 34494957

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg no load
Number of subjects: 996

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 996
Study: 35947082

Group type: EXPERIMENTAL
Intervention: 3.6 ml 2% mepivacaine hydrochloride with 1:100,000 adrenalin
Number of subjects: 330

Group type: COMPARATOR
Intervention: 3.4 ml 4% articaine hydrochloride with 1:100,000 adrenalin
Number of subjects: 330
Study: 34722430

Group type: EXPERIMENTAL
Intervention: SS group (simplified external cardiac massage trainer)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: RA group (Resusci Anne manikin)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (traditional simulation training with instructor feedback)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SS group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: RA group
Number of subjects: 60
Study: 34015465

Group type: EXPERIMENTAL
Intervention: Self-generation (SG) format
Number of subjects: 48

Group type: COMPARATOR
Intervention: Multiple-choice (MCQ) format
Number of subjects: 48
Study: 33048572

Group type: EXPERIMENTAL
Intervention: Single lapse cigarette
Number of subjects: 54

Group type: COMPARATOR
Intervention: No-lapse control condition
Number of subjects: 54
Study: 35988083

Group type: COMPARATOR
Intervention: Olfactory training (daily sessions for 3 months)
Number of subjects: 35
Study: 34036519

Group type: EXPERIMENTAL
Intervention: 5% human albumin
Number of subjects: 308

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 308
Study: 33349581

Group type: EXPERIMENTAL
Intervention: istradefylline
Number of subjects: 0

Group type: COMPARATOR
Intervention: preladenant
Number of subjects: 0

Group type: COMPARATOR
Intervention: tozadenant
Number of subjects: 0
Study: 32275360

Group type: EXPERIMENTAL
Intervention: Electronic moxibustion
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo moxibustion
Number of subjects: 59
Study: 35592965

Group type: EXPERIMENTAL
Intervention: Semi-autonomous AI application promoting dental recall visits
Number of subjects: 224
Study: 35105573

Group type: EXPERIMENTAL
Intervention: Sugammadex (SUG)
Number of subjects: 99
Study: 34195582

Group type: EXPERIMENTAL
Intervention: Cytosponge-TFF3 screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 35500264

Group type: EXPERIMENTAL
Intervention: Weekly subcutaneous semaglutide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daily liraglutide
Number of subjects: 0
Study: 34353646

Group type: EXPERIMENTAL
Intervention: Tape placed over the face mask at the bridge of the nose
Number of subjects: 123

Group type: COMPARATOR
Intervention: No tape over the mask/nose (Control)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Hospital-provided masks
Number of subjects: 123
Study: 32627595

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT‐I)
Number of subjects: 12
Study: 32027157

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) protocols for anxiety disorders
Number of subjects: 223
Study: 33637061

Group type: EXPERIMENTAL
Intervention: MOVE group treatment (MOVE-G)
Number of subjects: 300

Group type: COMPARATOR
Intervention: MOVE individual treatment (MOVE-I)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Both treatments (MOVE-G and MOVE-I)
Number of subjects: 300
Study: 32069067

Group type: EXPERIMENTAL
Intervention: Insulclock (Active group)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Insulclock (Overall population)
Number of subjects: 16
Study: 36004426

Group type: EXPERIMENTAL
Intervention: Standardized carbohydrate-rich snack (198 kcal) consumed in the morning
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Standardized carbohydrate-rich snack (198 kcal) consumed in the evening
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Standardized carbohydrate-rich snack (198 kcal) consumed in the afternoon
Number of subjects: 24
Study: 34049452

Group type: COMPARATOR
Intervention: Oral cannabis (10 mg THC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral cannabis (25 mg THC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vaporized cannabis (5 mg THC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vaporized cannabis (20 mg THC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: DRUID® test
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Field sobriety tests
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Blood THC concentrations after ingestion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Blood THC concentrations after inhalation
Number of subjects: 20
Study: 32016702

Group type: EXPERIMENTAL
Intervention: RESTORE intervention (individualized, physiotherapist-prescribed home program of weight-bearing balance and strength exercises, fall prevention advice)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: RESTORE intervention
Number of subjects: 336

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 336
Study: 35427708

Group type: EXPERIMENTAL
Intervention: Lithium monotherapy
Number of subjects: 31
Study: 33982406

Group type: EXPERIMENTAL
Intervention: Topical 1% cyclopentolate hydrochloride
Number of subjects: 6

Group type: COMPARATOR
Intervention: Topical 1% cyclopentolate hydrochloride combined with 2.5% phenylephrine
Number of subjects: 6
Study: 35165471

Group type: EXPERIMENTAL
Intervention: Cold flowable gutta‐percha
Number of subjects: 90
Study: 32918397

Group type: EXPERIMENTAL
Intervention: Standardized self-report measure for assessing patient reactions to diagnoses
Number of subjects: 1271

Group type: EXPERIMENTAL
Intervention: Schizophrenia diagnosis
Number of subjects: 1271

Group type: EXPERIMENTAL
Intervention: Anorexia nervosa diagnosis
Number of subjects: 1271
Study: 33776997

Group type: EXPERIMENTAL
Intervention: Galantamine 8 mg daily for 4 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Galantamine treatment
Number of subjects: 22
Study: 32212395

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention to prevent serious fall injuries
Number of subjects: 5451
Study: 34766790

Group type: COMPARATOR
Intervention: Institutional care (care as usual)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Foster care
Number of subjects: 271

Group type: COMPARATOR
Intervention: Never-institutionalized children
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Friendship quality (low quality)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Friendship quality (high quality)
Number of subjects: 271
Study: 34158524

Group type: EXPERIMENTAL
Intervention: Phrenic nerve block (PNB) with 2% lidocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with saline
Number of subjects: 0
Study: 614312649

Group type: EXPERIMENTAL
Intervention: Minimal volume of 1 mul fluorescein (mTBUT)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Conventional fluorescein strip (TBUT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Non-invasive method (NIBUT)
Number of subjects: 41
Study: 33557497

Group type: EXPERIMENTAL
Intervention: iRoot BP Plus
Number of subjects: 20

Group type: COMPARATOR
Intervention: MTA
Number of subjects: 20
Study: 32892963

Group type: EXPERIMENTAL
Intervention: CHANGE program (nutrition and behavior management strategies)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Parent education program (ASD education)
Number of subjects: 10
Study: 35929474

Group type: EXPERIMENTAL
Intervention: PVI-plus (extensive ablation)
Number of subjects: 469

Group type: COMPARATOR
Intervention: PVI-only (pulmonary vein isolation)
Number of subjects: 469
Study: 616388376

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam + Tanreqing injection
Number of subjects: 64

Group type: COMPARATOR
Intervention: Piperacillin-tazobactam
Number of subjects: 64
Study: 33724079

Group type: EXPERIMENTAL
Intervention: Genetically determined visceral adiposity (per 1 SD)
Number of subjects: 453702
Study: 32277344

Group type: EXPERIMENTAL
Intervention: Two-step infusion of imipenem (0.5 g q6h)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Two-step infusion of imipenem (1.0 g q8h)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Extended infusion of imipenem (0.5 g q6h)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Extended infusion of imipenem (1.0 g q8h)
Number of subjects: 35
Study: 33413049

Group type: EXPERIMENTAL
Intervention: AMCAFF (caffeine 3 mg/kg in the morning)
Number of subjects: 11

Group type: COMPARATOR
Intervention: PMPLAC (placebo in the evening)
Number of subjects: 11

Group type: COMPARATOR
Intervention: AMPLAC (placebo in the morning)
Number of subjects: 11
Study: 33531012

Group type: EXPERIMENTAL
Intervention: Warm bath
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Infrared radiation
Number of subjects: 12
Study: 35395548

Group type: EXPERIMENTAL
Intervention: Varenicline 2 mg/day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Varenicline 1 mg/day
Number of subjects: 25

Group type: COMPARATOR
Intervention: Varenicline 0 mg/day (placebo)
Number of subjects: 25
Study: 32900336

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate therapy (continuous infusion)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo (compound sodium lactate)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Monitoring with arterial blood gas analysis
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Duration of therapy until target pH is achieved
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Target pH
Number of subjects: 118
Study: 32911350

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 179